Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Stomach Neoplasms 56Carcinoma, Hepatocellular 42Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Lung Neoplasms 9Esophageal Neoplasms 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Glioma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

Nivolumab 20Ipilimumab 10Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Cancer × apatinib × Clear all
NCT03645200 2019-04-25

Treatment of Carrying TP53 Harmful Mutations

Tianjin Medical University Second Hospital

Phase 1 Unknown
60 enrolled

Advanced Cancer

NCT03243643 2017-09-08

HS:Hansoh;

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
80 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡